← Semnur Pharmaceuticals, Inc. (SMNR) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Semnur Pharmaceuticals, Inc. (SMNR)
Biotechnology · market cap $104M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Semnur Pharmaceuticals (SMNR) is a micro-staff (3-employee) clinical-stage biotech with a $1.38B market cap built almost entirely on one asset: SP-102, currently in Phase 2 for lumbosacral radicular pain (sciatica). Financial disclosures are sparse — cash position, runway, dilution history, and mechanism of action for SP-102 are not publicly confirmed in the provided data set. The company reported a net loss of approximately $160M in 2025 against negligible revenue and R&D spend of $3M.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SP-102 | Phase 2 | Lumbosacral Radicular Pain |
Price & technical context
3-month
-18.6%
6-month
-92.9%
12-month
-97.0%
52-wk range
$0.35–$23.00
vs 50-day MA
-10.6%
vs 200-day MA
-90.1%
Realized vol
288.1%
Max drawdown
-98.5%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SMNR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.